In October 2026, multiple advertising campaigns for over-the-counter drugs and parapharmaceutical products were published in newspapers and broadcast on television. These campaigns included updates about changes to medications available at a 15% discount beginning October 1st. One of the medications, Eliquis, experienced a notable price reduction in November, drawing attention from both consumers and industry observers. Pharmacy organizations stressed that the current focus was on ensuring transparency in pricing and practices rather than imposing additional taxes or regulations. Concerns were raised about a decline in young people opting to hold certain statuses, such as those related to healthcare benefits or eligibility for specific programs. Meanwhile, preparers noted that the CNP PPO, a type of health insurance plan, had a very busy start, indicating increased interest or enrollment. Dietary supplements designed to support metabolism were also highlighted in the campaigns, suggesting a growing consumer interest in products that claim to aid in weight management or energy levels. A new decree permitted doctors and nurses to begin stockpiling vaccines starting October 11, which could help ensure a steady supply during peak demand periods. In the field of oncology, or cancer treatment, improvements were noted in the delivery of Afinitor, a drug used to treat certain types of cancer. These improvements may relate to more efficient distribution or better patient access. Official health services emphasized the importance of clear communication in speeding up processes, such as approvals or patient care coordination. Pharmacists were also taking proactive steps in hypertension screening and follow-up care, with clearer schedules being established to improve patient outcomes. This focus on structured monitoring and communication reflects a broader effort to enhance public health management and ensure that patients receive timely and effective care.